At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
In Brief
A Phase 2 clinical trial evaluating Paclitaxel and CB-839 for Triple Negative Breast Cancer and TNBC - Triple-Negative Breast Cancer. Completed, enrolled 52 participants across 25 sites.
Detailed Summary
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMay 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedFeb 20, 2017
Enrollment StartMay 1, 2017
Primary CompletionNov 25, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.4 years ago
Interventions
Paclitaxeldrug
standard weekly paclitaxel in 28-day cycles
CB-839drug
CB-839 administered as oral tablets twice daily (BID)